Enter multiple symbols separated by commas

Amgen to Buy Kidney Disease Drug Company for $420 Million

Amgen said on Monday it has agreed to buy privately held Ilypsa, which is developing a drug for chronic kidney disease, for $420 million in cash.

Directors from each company and shareholders of Ilypsa have approved the proposed acquisition. The deal should close by the third quarter of 2007, the companies said.

Santa Clara, California-based Ilypsa's lead experimental drug candidate is ILY101, which is designed to treat hyperphosphatemia in chronic kidney disease in patients on hemodialysis.

Many large pharmaceutical companies are faced with looming patent expirations on drugs that bring in the majority of their sales and are buying smaller firms with promising products in a bid to secure future revenue.

Amgen's key products include anemia drugs Aranesp and Epogen, which are the focus of recent safety concerns.

Shares in Amgen closed down 3 cents to $56.91 on the Nasdaq, down about 18% from a year ago.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Hero miles for military members: Real estate magnate's plea

    Chairman of the Fisher House Foundation, Ken Fisher, discusses the Hero Miles program with CNBC's Dina Gusovsky. During Military Appreciation Month, Fisher is asking every traveler to donate 1,000 of their miles to replenish the Hero Miles programs that is in danger of running out.

  • Cramer shuts down this market's haters

    "Mad Money" host Jim Cramer on why this market can't stop, won't stop.

  • From the battlefield to the boardroom

    Your Grateful Nation is dedicated to helping Special Forces veterans enter the corporate world and Knot Standard provides complimentary suits to vets. Mad Money's Jim Cramer spoke with Rob Clapper, Your Grateful executive director; John Ballay, Knot Standard co-founder and president; Tej Gill, retired U.S. Navy Seal; and Darren McB, active duty U.S. Navy Seal.